Salix Pharmaceuticals and Progenics Pharmaceuticals announced the successful outcome of a recently completed Phase 3 trial evaluating the efficacy and safety of oral methylnaltrexone for the treatment of opioid-induced constipation.
Constipation commonly occurs in hospice and palliative care patients taking opioids for chronic pain. Methylnaltrexone is indicated for relief of opioid-induced constipation in these patients, when laxative therapy has been insufficient. Methylnaltrexone is a peripherally acting mu-opioid antagonist. It antagonizes the effects of opioids on peripheral tissues, including the gastrointestinal tract, without affecting the opioid’s analgesic effect. Methylnaltrexone is highly effective and well-tolerated, but is currently available only in injectable form for subcutaneous injection (brand name Relistor®).
The Phase 3 trial of oral methylnaltrexone evaluated three once-daily oral dosing regimens (150, 300 and 450 mg) and demonstrated highly statistically significant results in both the 300 and 450 mg treatment arms. Overall, efficacy of oral methylnaltrexone in this study was comparable to that reported in clinical studies of subcutaneous methylnaltrexone in subjects with chronic pain. The overall observed safety profile seen in patients treated with oral methylnaltrexone was comparable to placebo.
Salix and Progenics plan to submit a New Drug Application to the FDA in mid-2012.
|I believe it was an immediate-release tablet, but I can't be positive. That information was not specified in any of the articles I read.
-- Julia Harder
Posted 6/2/2012 06:30:30 PM
|IS it IR tablet or Enteric/delayed release tablet.
Posted 6/2/2012 06:30:08 PM
|I would love to know the estimated cost, too! At this point, having just completed phase III trials, the company has not released any cost information, so it’s hard to say whether it will be more cost-effective than subcutaneous Relistor. We will certainly update you when cost information becomes available.
-- Julia Harder
Posted 6/2/2012 06:29:40 PM
|Will the oral form be more cost effective than the SQ Relistor?
Would like to know the estimated cost.
-- Marsha Farrell RN-BC, CHPN
Posted 6/2/2012 06:29:03 PM
|First 10||<<Previous 10||Next 10 >>||Last 10|
Education Resources and Support for Hospices
Stay up-to-date on the latest hospice pharmacy benefits management information and tools with a variety of education resources and support at no extra charge. We offer presentations live at your facility, over the Internet or viateleconference, online service education programs, customized courses, and courses accredited for nursing continuing education credit.
Our palliative care experts provide clinical consulting on important medication management and care decisions. Our non-dispensing pharmacists provide focused attention and unbiased advice.
Why Use A PBM?
Contracting with multiple pharmacies, doing all the reporting, trying to stay current with medical practices and stay compliant while keeping costs down? There’s an easier and more effective way.